Literature DB >> 16836798

Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection.

L J Brant1, M Hurrelle, M A Balogun, P Klapper, F Ahmad, E Boxall, A Hale, V Hollyoak, I B Ibrahim, W Irving, R Meigh, K J Mutton, B C Patel, W K Paver, S Pugh, C Taylor, A J Turner, M E Ramsay.   

Abstract

This paper describes sentinel laboratory surveillance of hepatitis C antibody testing in England. Demographic and test result data were supplemented by follow-up questionnaires sent to the requesting clinician. Between October 2002 and September 2003 almost 75000 anti-HCV tests were performed in eight sentinel centres. More males were tested than females and over half of those tested were aged 25-44 years. Overall 5.7% (3333/58144, range 2.8-7.7%) individuals tested positive. Follow-up questionnaire data showed that 82% (1043/1277) of the positives had injecting drug use reported as the main risk exposure. The majority of negative individuals were undergoing routine screening as recommended for specific patient groups. Most individuals were asymptomatic. Antibody prevalence was estimated to be 34% in current injecting drug users and 42% in former injectors. Comparing positives to routine national surveillance suggests that only 53% (1782/3333) of diagnosed cases were reported. Sentinel laboratory data can provide valuable supplementary data to national surveillance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16836798      PMCID: PMC2870581          DOI: 10.1017/S0950268806006832

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  16 in total

1.  Lack of awareness of hepatitis C risk among persons who received blood transfusions before 1990.

Authors:  J Buffington; R Rowel; J M Hinman; K Sharp; S Choi
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

Review 2.  Hepatitis C: who is at risk and how do we identify them?

Authors:  D Goldberg; E Anderson
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

3.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

4.  Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.

Authors:  S M Bird; D J Goldberg; S J Hutchinson
Journal:  J Epidemiol Biostat       Date:  2001

5.  Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004.

Authors:  U Gungabissoon; M A Balogun; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-09-06       Impact factor: 2.451

6.  Surveillance of screening for hepatitis C through the laboratory network RENA-VHC, France, 2000-2001.

Authors:  C Meffre; C Larsen; A Perin; Laurence Bouraoui; E Delarocque Astagneau
Journal:  Euro Surveill       Date:  2003-05

7.  Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance.

Authors:  M A Balogun; H Laurichesse; M E Ramsay; J Sellwood; D Westmoreland; W K Paver; S F Pugh; M Zuckerman; D Pillay; T Wreghitt
Journal:  Commun Dis Public Health       Date:  2003-04

8.  The contribution of transfusion to HCV infection in England.

Authors:  K Soldan; M Ramsay; A Robinson; H Harris; N Anderson; E Caffrey; C Chapman; A Dike; G Gabra; A Gorman; A Herborn; P Hewitt; N Hewson; D A Jones; C Llewelyn; E Love; V Muddu; V Martlew; A Townley
Journal:  Epidemiol Infect       Date:  2002-12       Impact factor: 2.451

Review 9.  Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Authors:  Leonard B Seeff; Jay H Hoofnagle
Journal:  Clin Liver Dis       Date:  2003-02       Impact factor: 6.126

10.  A national survey of genitourinary medicine clinic attenders provides little evidence of sexual transmission of hepatitis C virus infection.

Authors:  M A Balogun; M E Ramsay; J V Parry; L Donovan; N J Andrews; J A Newham; C McGarrigle; K A Harris; C G Teo
Journal:  Sex Transm Infect       Date:  2003-08       Impact factor: 3.519

View more
  9 in total

1.  Can current national surveillance systems in England and Wales monitor sexual transmission of hepatitis C among HIV-infected men who have sex with men?

Authors:  Sarah Dougan; M Adekoyejo Balogun; Jonathan Elford; Lisa J Brant; Katy Sinka; Barry G Evans; Mary E Ramsay
Journal:  BMC Public Health       Date:  2007-01-18       Impact factor: 3.295

Review 2.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

3.  Human T-lymphotropic viruses (HTLV) in England and Wales, 2004 to 2013: testing and diagnoses.

Authors:  Georgina Ireland; Sara Croxford; Jennifer Tosswill; Rajani Raghu; Katy Davison; Patricia Hewitt; Ruth Simmons; Graham Taylor
Journal:  Euro Surveill       Date:  2017-05-18

4.  Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016.

Authors:  Georgina Ireland; Sema Mandal; Matthew Hickman; Mary Ramsay; Ross Harris; Ruth Simmons
Journal:  Euro Surveill       Date:  2019-07

5.  Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.

Authors:  Qiushi Chen; Turgay Ayer; Emily Bethea; Fasiha Kanwal; Xiaojie Wang; Mark Roberts; Yueran Zhuo; Stefano Fagiuoli; Jorg Petersen; Jagpreet Chhatwal
Journal:  BMJ Open       Date:  2019-06-11       Impact factor: 2.692

6.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

7.  Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017.

Authors:  G Ireland; R Simmons; M Hickman; M Ramsay; C Sabin; S Mandal
Journal:  Euro Surveill       Date:  2019-10

8.  The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.

Authors:  Jamie Inshaw; Clifford Leen; Martin Fisher; Richard Gilson; David Hawkins; Simon Collins; Julie Fox; Ken McLean; Sarah Fidler; Andrew Phillips; Sam Lattimore; Abdel Babiker; Kholoud Porter
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

9.  Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection.

Authors:  Sam Lattimore; Will Irving; Sarah Collins; Celia Penman; Mary Ramsay
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.